Blockchain Registration Transaction Record

Tonix to Present Tonmya Data at 2026 PainConnect Meeting

Tonix Pharmaceuticals will present Tonmya data at the 2026 PainConnect Annual Meeting. The company develops CNS and immunology treatments for fibromyalgia, depression, and rare diseases.

This announcement matters because it highlights ongoing advancements in treating chronic pain and mental health conditions that affect millions worldwide. Fibromyalgia alone impacts an estimated 2-4% of the global population, predominantly women, and has seen limited treatment innovation until Tonmya's recent approval. The presentation at a prestigious pain medicine conference suggests promising data that could expand treatment options beyond fibromyalgia to conditions like major depressive disorder and acute stress disorder, addressing significant unmet needs in mental healthcare. For patients suffering from these debilitating conditions, new therapeutic approaches could mean improved quality of life and symptom management. Additionally, Tonix's broader pipeline targeting rare diseases like Prader-Willi syndrome and conditions like Lyme disease prophylaxis demonstrates the company's commitment to addressing diverse medical challenges, potentially bringing novel solutions to underserved patient populations.